Find your next paid study

Mayo ClinicNCT07301268

Recurrent Glioblastoma, IDH-WildtypeRecurrent MGMT-Methylated Glioblastoma

A Phase 1 and Randomized Phase 2 Trial of Selinexor and Temozolomide in Recurrent Glioblastoma

This phase I/II trial tests the safety, side effects and best dose of selinexor given in combination with the usual chemotherapy (temozolomide) and compares th…

National Cancer Institute (NCI)NCT05432804

~$10 – $5,625

Diffuse Astrocytoma, IDH-MutantGlioblastoma, IDH-wildtypeBrain Metastases, Adult+18 more

An Open-label Phase 1/2 Dose Finding, Safety and Efficacy Study of Oral NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Uncontrolled Brain Metastasis in Patients With Select Solid Tumors.

This multi-site, Phase 1/2 clinical trial is an open-label study to identify the safety, pharmacokinetics, and efficacy of a repeated dose regimen of NEO212 al…

~$10 – $8,750

GlioblastomaGlioblastoma, IDH-WildtypeGliosarcoma+3 more

A Phase Ib Open Label Clinical Trial to Evaluate the Safety and Efficacy of ERAS-801 in Recurrent Glioblastoma or Elderly Newly Diagnosed Glioblastoma Patients With EGFR Amplification and/or Mutation (ERAS-801-3.0)

This phase Ib trial tests the safety and side effects of ERAS-801 in treating patients with isocitrate dehydrogenase (IDH) wildtype, epidermal growth factor re…

Jonsson Comprehensive Cancer CenterNCT07089641

Phase 2

A Randomized Trial to Assess the Efficacy and Safety of Cerebraca Wafer Plus Temozolomide Versus Temozolomide Alone in Recurrent Glioblastoma

This study is designed as a multi-center, randomized, open-label trial to evaluate the efficacy of Cerebraca Wafer in patients with recurrent glioblastoma. Cer…

Recurrent Glioblastoma, IDH-Wildtype

Everfront Biotech Co., Ltd.NCT07349693

~$10 – $8,750

Phase 3

A Randomized Phase III Study Comparing Temporally-Modulated Pulsed Radiation Therapy (TMPRT) Versus Standard Radiation Therapy With Temozolomide for Adults With Newly Diagnosed MGMT-Unmethylated Glioblastoma

This phase III trial compares temporally-modulated pulsed radiation therapy versus standard radiation therapy in treating patients with newly diagnosed, IDH wi…

Glioblastoma, IDH-WildtypeMGMT-Unmethylated Glioblastoma

~$10 – $7,500

NRG OncologyNCT07452458

Recurrent Glioblastoma, IDH-WildtypeRecurrent WHO Grade 2 GliomaRecurrent WHO Grade 3 Glioma+1 more

A Phase 1 Adaptive Dose Escalation With Dose Expansion Study of Triapine in Combination With Temozolomide (TMZ) for Patients With Recurrent Glioblastoma

This phase I trial tests the safety, side effects, and best dose of triapine in combination with temozolomide in treating patients with glioblastoma that has c…

Northwestern UniversityNCT06410248

Phase 2

Randomized Phase II Trial to Evaluate the Efficacy of WSD0922-FU When Combined With Adjuvant Temozolomide in Patients With EGFR Mutant Glioblastoma

This phase II trial compares the effect of adding WSD0922-FU to temozolomide versus temozolomide alone in slowing disease progression in patients with Epiderma…

Glioblastoma, IDH-Wildtype

Mayo ClinicNCT07708961

Astrocytoma, IDH-Mutant, Grade 2Recurrent Adult Diffuse Hemispheric Glioma, H3 G34-MutantRecurrent Adult Diffuse Midline Glioma, H3 K27-Mutant+4 more

A Phase I Trial Combining Triapine With Radiation Therapy for Recurrent Glioblastoma or Astrocytoma

This phase I trial tests the safety, side effects, and best dose of triapine in combination with radiation therapy in treating patients with glioblastoma or as…

National Cancer Institute (NCI)NCT06860594

~$10 – $5,625

Phase 2

Phase II Glioblastoma Accelerated Biomarkers Learning Environment Trial (GABLE)

This phase II trial studies whether different imaging techniques can provide additional and more accurate information than the usual approach for assessing the…

Glioblastoma, IDH-Wildtype

ECOG-ACRIN Cancer Research GroupNCT06319027

~$10 – $7,500

Observational

Phase II Randomized Trial Of Glucose Monitoring In Glioblastoma

This clinical trial studies whether continuous glucose monitoring (CGM) can be used to help patients with glioblastoma manage their blood sugar (glucose) level…

Glioblastoma, IDH-WildtypeWHO Grade 4 Glioma

Mayo ClinicNCT07091864

Recurrent Astrocytoma, IDH-Mutant, Grade 4Recurrent Glioblastoma, IDH-Wildtype

A Phase 1 Trial to Evaluate the Safety of EGFR/IL13Rα2 Pool-CAR T Cells in Patients With Recurrent or Progressive High-Grade Glioma (HGG)

This phase I trial studies the side effects and best dose of EGFR/IL13Rα2 pool-chimeric antigen receptor (CAR) T cells when given through a thin, flexible tube…